DDInter1042 DDInter474
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Dapagliflozin {u} (Compound) binds {v} (Gene) UGT1A9
Dapagliflozin {u} (Compound) is included by {v} (Pharmacologic Class) Sodium-Glucose Transporter 2 Inhibitors
Dapagliflozin {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Simvastatin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexpiprazole
Dapagliflozin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Dapagliflozin (Compound) binds UGT1A9 (Gene)
Dapagliflozin (Compound) is included by Sodium-Glucose Transporter 2 Inhibitors (Pharmacologic Class)
Dapagliflozin (Compound) causes Hypoglycaemia (Side Effect)
Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Dapagliflozin may lead to a major life threatening interaction when taken with Gatifloxacin